Monitor for additional HHS task orders or modifications under this contract vehicle, which could expand the total value. Leidos' backlog and revenue visibility in health services may see a modest incremental benefit.
Price Chart
Executive Summary
Leidos Holdings subsidiary Leidos Biomedical Research received a $72.2M contract from HHS for functional precision medicine and response assays. The award is a meaningful but not transformative addition to Leidos' government services pipeline, reinforcing its position in health and biomedical research contracting.
Key Financial Metrics
Key Facts
- Award amount: $72,167,416 from the Department of Health and Human Services
- Recipient: Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings
- Contract period begins September 29, 2026
- Scope: functional precision medicine and response assays
Financial Impact
$72.2M contract award; annual revenue of Leidos is not stated, so percentage impact cannot be calculated
Risk Factors
- Government funding subject to continuing resolutions or appropriations risk
- Execution risk on specialized biomedical assay work
- Contract may be a single award with no guarantee of follow-on orders
Investment Themes
Documents Analyzed
This report is based on 1 federal contract record from official U.S. government contract data.
| Document | Accession Number |
|---|---|
| GOVT-CONTRACT Data (Synthetic) | contract-75N91026F00034 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | Institutional Cluster | $136.18 | awaiting T+20 | — | $139.96 (+2.78%) |
Oct 14, 2026 12d ago | Press Release | $120.59 | awaiting T+20 | — | $139.96 (+16.06%) |
Oct 13, 2026 13d ago | GOVT-CONTRACT | $120.59 | awaiting T+20 | — | $139.96 (+16.06%) |
Oct 6, 2026 20d ago | Press Release | $116.69 | awaiting T+20 | — | $139.96 (+19.94%) |
Oct 5, 2026 21d ago | 8-K | $119.45 | awaiting T+20 | — | $139.96 (+17.17%) |
Oct 1, 2026 25d ago | 8-K | $121.97 | awaiting T+20 | — | $139.96 (+14.75%) |
Sep 29, 2026 27d ago | Press Release | $123.10 | awaiting T+20 | — | $139.96 (+13.70%) |
Sep 29, 2026 27d ago | GOVT-CONTRACT | $121.83 | awaiting T+20 | — | $139.96 (+14.88%) |
Sep 29, 2026 27d ago | GOVT-CONTRACT | $121.83 | awaiting T+20 | — | $139.96 (+14.88%) |
Sep 25, 2026 4w ago | GOVT-CONTRACT | $122.35 | awaiting T+20 | — | $139.96 (+14.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers